Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature

por Pelgrims, J, Vos, F De, Brande, J Van den, Schrijvers, D, Prové, A, Vermorken, J B
Publicado 2000

A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours

por Rasschaert, M, Schrijvers, D, Van den Brande, J, Dyck, J, Bosmans, J, Merkle, K, Vermorken, J B
Publicado 2007

Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment

por Michalides, R, van Tinteren, H, Balkenende, A, Vermorken, J B, Benraadt, J, Huldij, J, van Diest, P
Publicado 2002

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: re...

por Vermorken, J. B., Psyrri, A., Mesía, R., Peyrade, F., Beier, F., de Blas, B., Celik, I., Licitra, L.
Publicado 2014

Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.

por Honkoop, A. H., Hoekman, K., Wagstaff, J., van Groeningen, C. J., Vermorken, J. B., Boven, E., Pinedo, H. M.
Publicado 1996

Phase I study of gemcitabine using a once every 2 weeks schedule.

por Vermorken, J. B., Guastalla, J. P., Hatty, S. R., Seitz, D. E., Tanis, B., McDaniels, C., Clavel, M. D.
Publicado 1997

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions

por Haddad, R I, Posner, M, Hitt, R, Cohen, E E W, Schulten, J, Lefebvre, J -L, Vermorken, J B
Publicado 2018

Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translation...

por Psyrri, A., Licitra, L., Lacombe, D., Schuuring, E., Budach, W., Ozsahin, M., Knecht, R., Vermorken, J. B., Langendijk, J. A.
Publicado 2010

KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis

por Deschoolmeester, V, Boeckx, C, Baay, M, Weyler, J, Wuyts, W, Van Marck, E, Peeters, M, Lardon, F, Vermorken, J B
Publicado 2010

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part

por Vermorken, J B, Guigay, J, Mesia, R, Trigo, J M, Keilholz, U, Kerber, A, Bethe, U, Picard, M, Brummendorf, T H
Publicado 2011

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.

por Sulkes, A., Smyth, J., Sessa, C., Dirix, L. Y., Vermorken, J. B., Kaye, S., Wanders, J., Franklin, H., LeBail, N., Verweij, J.
Publicado 1994

The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.

por Schuurhuis, G. J., Broxterman, H. J., Pinedo, H. M., van Heijningen, T. H., van Kalken, C. K., Vermorken, J. B., Spoelstra, E. C., Lankelma, J.
Publicado 1990

The role of apoptotic cell death in the radiosensitising effect of gemcitabine

por Pauwels, B, Vermorken, J B, Wouters, A, Ides, J, Van Laere, S, Lambrechts, H A J, Pattyn, G G O, Vermeulen, K, Meijnders, P, Lardon, F
Publicado 2009

In vitro interaction between Ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects

por Simoens, C, Korst, A E C, De Pooter, C M J, Lambrechts, H A J, Pattyn, G G O, Faircloth, G T, Lardon, F, Vermorken, J B
Publicado 2003

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metasta...

por Licitra, L., Mesia, R., Rivera, F., Remenár, É., Hitt, R., Erfán, J., Rottey, S., Kawecki, A., Zabolotnyy, D., Benasso, M., Störkel, S., Senger, S., Stroh, C., Vermorken, J. B.
Publicado 2011

Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies

por Thertulien, R., Manikhas, G. M., Dirix, L. Y., Vermorken, J. B., Park, K., Jain, M. M., Jiao, J. J., Natarajan, J., Parekh, T., Zannikos, P., Staddon, A. P.
Publicado 2011

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

por Moorsel, C J A van, Pinedo, H M, Veerman, G, Bergman, A M, Kuiper, C M, Vermorken, J B, van der Vijgh, W J F, Peters, G J
Publicado 1999

Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.

por Elferink, F., van der Vijgh, W. J., ten Bokkel Huinink, W. W., Vermorken, J. B., Klein, I., Winograd, B., Knobf, M. K., Simonetti, G., Gall, H. E., McVie, J. G.
Publicado 1987

EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer

por Van den Brande, J, Schöffski, P, Schellens, J H M, Roth, A D, Duffaud, F, Weigang-Köhler, K, Reinke, F, Wanders, J, de Boer, R F, Vermorken, J B, Fumoleau, P
Publicado 2003

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

por Mesía, R., Rivera, F., Kawecki, A., Rottey, S., Hitt, R., Kienzer, H., Cupissol, D., De Raucourt, D., Benasso, M., Koralewski, P., Delord, J.-P., Bokemeyer, C., Curran, D., Gross, A., Vermorken, J. B.
Publicado 2010